Results From Sequana Medical’s RED DESERT alfapump DSR® Study Selected for Presentation at the Heart Failure 2021 Online Congress
June 09, 2021 01:00 ET
|
Sequana Medical
GHENT, Belgium, June 09, 2021 (GLOBE NEWSWIRE) -- Sequana Medical NV (Euronext Brussels: SEQUA, the "Company" or "Sequana Medical"), an innovator in the treatment of diuretic-resistant fluid...
Sequana Medical Announces First Patient Enrolled in SAHARA DESERT
June 01, 2021 01:00 ET
|
Sequana Medical
GHENT, Belgium, June 01, 2021 (GLOBE NEWSWIRE) -- Sequana Medical NV (Euronext Brussels: SEQUA), an innovator in the treatment of diuretic-resistant fluid overload in liver disease, malignant...
Sequana Medical Announces Strong Top-Line Results from RED DESERT alfapump DSR® Study and Expansion of DSR® Development Programme
May 11, 2021 01:00 ET
|
Sequana Medical
RED DESERT data of all patients confirm: alfapump DSR is highly effective at managing fluid and sodium balance in diuretic-resistant heart failure patients without need for loop diuretics...
Sequana Medical Announces Annual and Extraordinary General Meetings of Shareholders on 27 May 2021
April 27, 2021 01:00 ET
|
Sequana Medical
GHENT, Belgium, April 27, 2021 (GLOBE NEWSWIRE) -- Sequana Medical NV (Euronext Brussels: SEQUA) (the "Company" or "Sequana Medical"), an innovator in the treatment of diuretic-resistant fluid...
Sequana Medical Announces New Share Capital Amount and New Number of Shares
March 25, 2021 13:00 ET
|
Sequana Medical
GHENT, Belgium, March 25, 2021 (GLOBE NEWSWIRE) -- Sequana Medical NV (Euronext Brussels: SEQUA) (the “Company” or “Sequana Medical”), an innovator in the treatment of diuretic-resistant fluid...
Sequana Medical Announces 2020 Full Year Results and 2021 Outlook
March 17, 2021 01:00 ET
|
Sequana Medical
POSEIDON – positive interim results in Q4 2020; additional interim results expected inQ2 2021 and primary endpoint in Q2 2022RED DESERT – positive interim results in Q4 2020; top-line data expected in...
Sequana Medical Notice of 2020 Full Year Results and Business Update
March 10, 2021 01:00 ET
|
Sequana Medical
GHENT, Belgium, March 10, 2021 (GLOBE NEWSWIRE) -- Sequana Medical NV (Euronext Brussels: SEQUA), an innovator in the treatment of diuretic-resistant fluid overload in liver disease, malignant...
Sequana Medical's New Share Capital Amount and New Number of Shares
February 16, 2021 01:00 ET
|
Sequana Medical
GHENT, Belgium, Feb. 16, 2021 (GLOBE NEWSWIRE) -- Sequana Medical NV (Euronext Brussels: SEQUA) (the "Company" or "Sequana Medical"), an innovator in the treatment of diuretic-resistant fluid...
Sequana Medical announces February-March 2021 Investor Conference Schedule
February 15, 2021 01:00 ET
|
Sequana Medical
GHENT, Belgium, Feb. 15, 2021 (GLOBE NEWSWIRE) -- Sequana Medical NV (Euronext Brussels: SEQUA, the “Company”), an innovator in the treatment of diuretic-resistant fluid overload in liver disease,...
Sequana Medical Announces Granting of Key alfapump DSR® Patents in U.S. and Europe
February 04, 2021 01:00 ET
|
Sequana Medical
GHENT, Belgium, Feb. 04, 2021 (GLOBE NEWSWIRE) -- Sequana Medical NV (Euronext Brussels: SEQUA), an innovator in the treatment of diuretic-resistant fluid overload in liver disease, malignant...